Page last updated: 2024-12-07
adenylyl-(2'-5')-uridine
Description
Adenylyl-(2'-5')-uridine (2-5A) is a naturally occurring oligonucleotide that acts as a potent antiviral agent. It is synthesized by 2-5A synthetase, an enzyme activated by double-stranded RNA (dsRNA), a hallmark of viral infection. 2-5A binds to and activates an endoribonuclease known as RNase L, leading to the degradation of viral mRNA and inhibiting viral protein synthesis. 2-5A is extensively studied for its potential antiviral activity, particularly against RNA viruses like influenza, HIV, and hepatitis C. The synthesis, structure, and activity of 2-5A, as well as its role in antiviral immunity, are subjects of ongoing research. Its potential as a therapeutic agent is being explored. '
adenylyl-(2'-5')-uridine: see also record for uridylyl-(2'-5')-adenosine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 112074 |
| SCHEMBL ID | 8611259 |
| MeSH ID | M0098033 |
Synonyms (10)
| Synonym |
|---|
| [(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-yl] [(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl hydrogen phosphate |
| phosphoric acid 5-(6-amino-purin-9-yl)-4-hydroxy-2-hydroxymethyl-tetrahydro-furan-3-yl ester 5-(2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl ester |
| uridylyl(5'.2')adenosine |
| adenylyl-(3'-5')-uridine |
| adenosine, uridylyl-(5'-2')- |
| adenylyl-(2'-5')-uridine |
| einecs 233-196-3 |
| SCHEMBL8611259 |
| adenylyl-(3'-->5')-uridine |
| DTXSID901312908 |
Drug Classes (2)
| Class | Description |
|---|
| nucleoside analogue | An analogue of a nucleoside, being an N-glycosyl compound in which the nitrogen-containing moiety is a modified nucleotide base. They are commonly used as antiviral products to prevent viral replication in infected cells. |
| purines | A class of imidazopyrimidines that consists of purine and its substituted derivatives. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 4 (80.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.51
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.51 (24.57) | | Research Supply Index | 1.79 (2.92) | | Research Growth Index | 4.31 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |